Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
07:30am, Monday, 23'rd Sep 2024
Many healthcare companies are working hard now on developing the next big weight loss drug. Industry veteran Amgen has an exciting treatment that may not require frequent injections.
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
07:45am, Thursday, 19'th Sep 2024
Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%,
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
05:49am, Wednesday, 18'th Sep 2024
Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
06:57pm, Monday, 16'th Sep 2024
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell
11:42am, Saturday, 14'th Sep 2024
Jim Cramer is probably the closest thing we have to stock market superstar influencer.
These 2 Biotech Stocks Are Set to Soar
06:45am, Friday, 13'th Sep 2024
Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
03:51am, Friday, 13'th Sep 2024
Roche, a big pharmaceutical company, recently shared details from an early-stage trial with its oral anti-obesity candidate. Roche's oral anti-obesity candidate outperformed a similar candidate from V
Why Investors Plowed Into Viking Therapeutics Stock Today
07:12pm, Thursday, 12'th Sep 2024
Many investors and prognosticators think one investigational drug in particular has vast potential. If ultimately approved, VK2735 would surely be competitive in a highly popular segment.
Five Top Obesity Stocks to Buy and Hold Long Term
11:50am, Thursday, 12'th Sep 2024
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Thursday, 12'th Sep 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
04:15am, Thursday, 12'th Sep 2024
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have decline
Why Viking Therapeutics Stock Rocked the Market Today
05:08pm, Wednesday, 11'th Sep 2024
An analyst initiated coverage of the biotech. He's optimistic about its future, to put it mildly.
Why Analysts Predict a November Surge for Viking Therapeutics Stock
04:50pm, Wednesday, 11'th Sep 2024
Viking Therapeutics (VKTX) shares rose more than 10% Wednesday after J.P. Morgan analysts initiated coverage of the company with an "overweight" rating and a price target of $80 per share, calling the
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
01:55pm, Wednesday, 11'th Sep 2024
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its curre
These 12 Stocks are Ripe for a Short Squeeze
10:51am, Tuesday, 10'th Sep 2024
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
